ReviewMolecular diagnosis & therapy2014
Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential.
Review in Molecular diagnosis & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Circulating tumor cells as biomarkers in melanoma: techniques, challenges, and clinical applications.Frontiers in cell and developmental biology · 2026Review
- Pair-matched analysis of Circulating Melanoma Cells (CMCs) before and after Immunotherapy in Relation to other Melanoma-Specific Biomarkers.Journal of Cancer · 2025Article
- Dielectrophoretic capture and electrochemical enzyme-linked immunosorbent assay of single melanoma cells at an array of interlocked spiral bipolar electrodes.ChemElectroChem · 2024Article
- Article
- Significance of 5-International journal of molecular sciences · 2020Review
- Melanoma in the Eyes of Mechanobiology.Frontiers in cell and developmental biology · 2020Review
- Real-Time Measurement of Melanoma Cell-Mediated Human Brain Endothelial Barrier Disruption Using Electric Cell-Substrate Impedance Sensing Technology.Biosensors · 2019Article
- Circulating cell-free DNA does not harbour a diagnostic benefit in cats with feline diffuse iris melanomas.Journal of feline medicine and surgery · 2019Article
- Liquid biomarkers in melanoma: detection and discovery.Molecular cancer · 2018Review
- Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146.Cell death discovery · 2017Review
- Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.The oncologist · 2016Review
- New therapeutic targets for cancer bone metastasis.Trends in pharmacological sciences · 2015Review
- Dormancy of growth-stunted malignant melanoma: sustainable and smoldering patterns.Oncology reviews · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Circulating melanoma cells (CMCs) are thought to be the foundation for metastatic disease, which makes this cancer especially lethal. Cancer cells contained in the primary tumor undergo genotypic and phenotypic changes leading to an epithelial-to-mesenchymal transition, during which numerous changes occur in signaling pathways and proteins in the cells. CMCs are then shed off or migrate from the primary tumor and intravasate the vasculature system. A few CMCs are able to survive in the circulation through expression of a variety of genes and also by evading immune system recognition to establish metastases at distant sites after extravasating from the vessels. The presence of CMCs in the blood of a melanoma patient can be used for disease staging, predicting metastasis development, and evaluating the efficacy of therapeutic agents. Overall survival and disease-free duration can also be correlated with the presence of CMCs. Finally, analysis of CMCs for druggable therapeutic gene targets could lead to the development of personalized treatment regimens to prevent metastasis. Thus, the study of CMCs shows promise for the detection, staging, and monitoring of disease treatment, as well as for determination of prognosis and predicting overall disease-free survival. These are the areas reviewed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.